AVROBIO Receives Rare Pediatric Disease Designation from the U.S. FDA for AVR-RD-05, a Gene Therapy for Mucopolysaccharidosis Type II (MPSII) or Hunter Syndrome

Rhea-AI Summary

AVROBIO, a clinical-stage gene therapy company, has received Rare Pediatric Disease Designation from the FDA for its lentiviral gene therapy, AVR-RD-05, aimed at treating Hunter syndrome. This designation is part of a program that promotes the development of treatments for rare pediatric diseases. The first Phase 1/2 clinical trial for AVR-RD-05 is expected to begin in the second half of 2022. Hunter syndrome affects 1 in 100,000 to 170,000 males globally, leading to serious health complications.

Positive

• FDA granted Rare Pediatric Disease Designation for AVR-RD-05, facilitating potential future marketing applications.
• Phase 1/2 clinical trial for AVR-RD-05 planned to begin in the second half of 2022, indicating progress in clinical development.

Negative

• None.

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation to AVR-RD-05, its lentiviral gene therapy for the treatment of mucopolysaccharidosis type II (MPSII), or Hunter syndrome, a rare and seriously debilitating lysosomal disorder that primarily affects young boys.

The FDA’s Rare Pediatric Disease Designation and Voucher Program is intended to facilitate the development of new drugs and biologics for the prevention and treatment of rare pediatric diseases. Companies that receive approval for a new drug application or Biologics License Application (BLA) for a rare pediatric disease may be eligible to receive a voucher for a priority review of a subsequent marketing application for a different product. The priority review voucher may be used by the company or sold to a third party.

The company’s planned investigator-sponsored Phase 1/2 clinical trial for Hunter syndrome is expected to commence in the second half of 2022. The program was developed by Brian Bigger, Ph.D., professor of cell and gene therapy at the University of Manchester, U.K. Prof. Bigger has published preclinical data demonstrating that ex vivo lentiviral gene therapy deploying an optimized, proprietary tag has the potential to correct peripheral disease and normalize brain pathology.

Hunter syndrome, which affects an estimated one in 100,000 to one in 170,000 males worldwide, causes devastating complications throughout the body and brain, including severe cardiac and respiratory dysfunction, skeletal malformations and hearing impairment. Children with severe cases of Hunter syndrome typically show early symptoms of the disease in their toddler years and begin to regress developmentally, losing basic motor skills and cognitive function over a few years. The current standard of care is weekly enzyme replacement therapy (ERT), which can delay some health complications but does not halt overall progression of the disease and has not been demonstrated to address the central nervous system (CNS) issues. Even with ERT, people with Hunter syndrome face life-limiting symptoms and a significantly reduced lifespan.

About AVROBIO
Our vision is to bring personalized gene therapy to the world. We aim to prevent, halt or reverse disease throughout the body with a single dose of gene therapy designed to drive durable expression of therapeutic protein, even in hard-to-reach tissues and organs including brain, muscle and bone. Our ex vivo lentiviral gene therapy pipeline includes clinical programs in Fabry disease, Gaucher disease type 1 and cystinosis as well as preclinical programs in Hunter syndrome, Gaucher disease type 3 and Pompe disease. AVROBIO is powered by our industry-leading plato® gene therapy platform, our foundation designed to deliver gene therapy worldwide. We are headquartered in Cambridge, Mass., with an office in Toronto, Ontario. For additional information, visit avrobio.com, and follow us on Twitter and LinkedIn.

Forward-Looking Statements
This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words and phrases such as “aims,” “anticipates,” “believes,” “could,” “designed to,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will,” and variations of these words and phrases or similar expressions that are intended to identify forward-looking statements. These forward-looking statements include, without limitation, statements regarding our business strategy for and the potential therapeutic benefits of our product candidates, the design, commencement, enrollment and timing of ongoing or planned clinical trials, clinical trial results, product approvals and regulatory pathways, anticipated benefits of the FDA’s Rare Pediatric Disease Designation for AVR-RD-05, our plans and expectations with respect to the development of AVR-RD-05, including timing of our planned investigator-sponsored clinical trial for such product candidate, anticipated benefits of our gene therapy platform including potential impact on our commercialization activities, timing and likelihood of success, the expected benefits and results of our implementation of the plato® platform in our clinical trials and gene therapy programs, and the expected safety profile of our investigational gene therapies. Any such statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Results in preclinical or early-stage clinical trials may not be indicative of results from later stage or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements, or the scientific data presented.

Any forward-looking statements in this press release are based on AVROBIO’s current expectations, estimates and projections about our industry as well as management’s current beliefs and expectations of future events only as of today and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that any one or more of AVROBIO’s product candidates will not be successfully developed or commercialized, the risk of cessation or delay of any ongoing or planned clinical trials of AVROBIO or our collaborators, the risk that regulatory agencies may disagree with our anticipated development approach for our product candidates such as AVR-RD-05, the risk that AVROBIO may not successfully recruit or enroll a sufficient number of patients for our clinical trials, the risk that AVROBIO may not realize the intended benefits of our gene therapy platform, including the features of our plato® platform, the risk that our product candidates or procedures in connection with the administration thereof will not have the safety or efficacy profile that we anticipate, the risk that prior results, such as signals of safety, activity or durability of effect, observed from preclinical or clinical trials, will not be replicated or will not continue in ongoing or future studies or trials involving AVROBIO’s product candidates, the risk that we will be unable to obtain and maintain regulatory approval for our product candidates, the risk that the size and growth potential of the market for our product candidates will not materialize as expected, risks associated with our dependence on third-party suppliers and manufacturers, risks regarding the accuracy of our estimates of expenses and future revenue, risks relating to our capital requirements and needs for additional financing, risks relating to clinical trial and business interruptions resulting from the COVID-19 outbreak or similar public health crises, including that such interruptions may materially delay our enrollment and development timelines and/or increase our development costs or that data collection efforts may be impaired or otherwise impacted by such crises, and risks relating to our ability to obtain and maintain intellectual property protection for our product candidates. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause AVROBIO’s actual results to differ materially and adversely from those contained in the forward-looking statements, see the section entitled “Risk Factors” in AVROBIO’s most recent Quarterly Report, as well as discussions of potential risks, uncertainties and other important factors in AVROBIO’s subsequent filings with the Securities and Exchange Commission. AVROBIO explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211103005366/en/

Investor:

Christopher F. Brinzey

ICR Westwicke

339-970-2843

chris.brinzey@westwicke.com

Media:

Kit Rodophele

Ten Bridge Communications

617-999-9620

krodophele@tenbridgecommunications.com

Source: AVROBIO, Inc.

FAQ

What is the significance of the FDA's Rare Pediatric Disease Designation for AVROBIO's AVR-RD-05?

The designation facilitates the development of AVR-RD-05 for Hunter syndrome and may allow for a priority review voucher for future applications.

When will the Phase 1/2 clinical trial for AVR-RD-05 start?

The Phase 1/2 clinical trial is expected to commence in the second half of 2022.

What condition does AVR-RD-05 aim to treat?

AVR-RD-05 is designed to treat Hunter syndrome, a rare genetic disorder.

How common is Hunter syndrome worldwide?

Hunter syndrome affects an estimated 1 in 100,000 to 170,000 males globally.

What are the typical symptoms of Hunter syndrome?

Symptoms include severe cardiac and respiratory dysfunction, skeletal malformations, and cognitive decline.